Phylloceuticals
Phylloceuticals is a technology company focused on revolutionizing the production of therapeutics using the simplest of plants. They aim to bring safer, faster, and cheaper therapeutics to market, with a focus on social impact, national security, and broadening access to critical therapeutics globally. Their technology offers a reduced-risk, clean-profile solution for plant-based pharmaceuticals.
Industries
Nr. of Employees
small (1-50)
Phylloceuticals
Philadelphia, Pennsylvania, United States, North America
Products
Plant-produced biosimilars and biobetters
Plant-expressed versions of established biologic therapeutics intended to supply Phase I/II clinical studies and post-patent commercial markets with lower-cost, scalable product.
Plant-produced biosimilars and biobetters
Plant-expressed versions of established biologic therapeutics intended to supply Phase I/II clinical studies and post-patent commercial markets with lower-cost, scalable product.
Services
CDMO/CMO services covering IND-enabling development, clinical production, and commercial manufacturing of plant-expressed biologics.
Design, installation and operation of modular pilot facilities and micro-scale manufacturing units for regional or point-of-care production.
Collaborative preclinical programs that integrate computational and AI-driven discovery methods with plant-based expression workflows to accelerate candidate identification.
CDMO/CMO services covering IND-enabling development, clinical production, and commercial manufacturing of plant-expressed biologics.
Design, installation and operation of modular pilot facilities and micro-scale manufacturing units for regional or point-of-care production.
Collaborative preclinical programs that integrate computational and AI-driven discovery methods with plant-based expression workflows to accelerate candidate identification.
Expertise Areas
- Plant-made biologics manufacturing
- CMO/CDMO services for biologics
- Process development and scale-up
- Regulatory compliance and IND enabling
Key Technologies
- Plant-based expression systems
- Modular pilot facility biomanufacturing
- Bioreactor process development
- Genetic engineering of plants
News & Updates
January 30th, 2025: Phylloceuticals launches a pilot facility in Rapid City, supporting plant-based pharmaceuticals.
Susan Stipa delivered a recent pitch to a local Angel fund group
March 2025: Susan Stipa presented to a local angel fund group.
January 9th, 2025: Market expected to reach USD 24.9 million by 2027.
January 30th, 2025: Phylloceuticals launches a pilot facility in Rapid City, supporting plant-based pharmaceuticals.
Susan Stipa delivered a recent pitch to a local Angel fund group
March 2025: Susan Stipa presented to a local angel fund group.
January 9th, 2025: Market expected to reach USD 24.9 million by 2027.